← Eichor
Condition: Cd7 T All Lbl Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cd7 T All Lbl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
Phase 1 · 1 location(s) · Peking University People's Hospital · NCT07280494SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07153068Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
NA · 1 location(s) · Hebei Senlang Biotechnology Inc., Ltd. · NCT05626400CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
Phase 1 · 1 location(s) · Hebei Senlang Biotechnology Inc., Ltd. · NCT06136364
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.